Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Present Brilinta Panel With Alternative Explanation For Negative U.S. Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reviewers discredit AstraZeneca's suggestion that higher doses of aspirin explain ticagrelor's discordant results for U.S. versus overall trial participants - but also offer an alternative reason for the findings.
Advertisement

Related Content

AstraZeneca's Brilinta Approved With Aspirin Warning
AstraZeneca's Brilinta Approved With Aspirin Warning
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta
Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta
Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results
AstraZeneca: Aspirin May Be To Blame For Poor Results In Some Brilinta Trial Patients
Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts
Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts

Topics

Advertisement
UsernamePublicRestriction

Register

PS070959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel